These allogeneic CD33-CAR-T cells would represent a promising option for AML treatment, especially for therapeutic approaches in R/R AML patients where CAR-T cells are used to reduce tumor burden as bridging therapy prior to allogeneic stem cell transplantation. This evidence concerns the gene CD33 and acute myeloid leukemia.